OliPass
Exon Skipping Therapeutics Company
- Founded
- 2006
- Website
- olipass.com
About
OliPass develops artificial nucleic acid therapeutics using its proprietary peptide nucleic acid platform. The company modifies peptide nucleic acids with cationic groups to improve cell permeability and binding affinity to target pre-mRNA in the nucleus. Its research focuses on using this platform to modulate disease-causing genes, induce exon skipping, and create therapeutic candidates intended to address diseases without requiring special formulation.
Summary
OliPass is a Biotech company, founded in 2006.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/olipass"><img src="https://indexed.vc/api/badge/company/olipass" alt="OliPass on Indexed.vc" width="260" height="76" /></a>